First year real life experience with tenofovir alafenamide fumarate: The pythagorean cohort

Basit Öğe Kaydı
dc.authoridmete, ayşe özlem/0000-0003-0994-4465
dc.authoridHarputluoglu, Muhsin Murat Muhip/0000-0002-9415-147X
dc.authorwosidKarasahin, Omer/JBJ-0597-2023
dc.authorwosidkandemir, özlem/KAP-1812-2024
dc.authorwosidmete, ayşe özlem/AAA-5072-2021
dc.authorwosidTaşova, Yeşim/JVY-8831-2024
dc.authorwosidyıldız, yeşim/AAD-2219-2022
dc.authorwosidHarputluoglu, Muhsin Murat Muhip/ABI-3094-2020
dc.contributor.authorKarasahin, Omer
dc.contributor.authorKalkan, Irem Akdemir
dc.contributor.authorDal, Tuba
dc.contributor.authorToplu, Sibel Altunisik
dc.contributor.authorHarputluoglu, Murat
dc.contributor.authorMete, Ayse Ozlem
dc.contributor.authorKomur, Suheyla
dc.date.accessioned2024-08-04T20:10:21Z
dc.date.available2024-08-04T20:10:21Z
dc.date.issued2023
dc.departmentİnönü Üniversitesien_US
dc.description.abstractBackground and Aim: In chronic hepatitis B infection, antiviral therapy significantly reduces the incidence of complications. This study aimed to present real-life 12-month effectiveness and safety data for TAF.Materials and Methods: This Pythagoras Retrospective Cohort Study included patients from 14 centers in Turkiye. The study presents 12-month results of 480 patients treated with TAF as initial therapy or after switching from another antiviral drug.Results: The study shows treatment of about 78.1% patients with at least one antiviral agent (90.6% tenofovir disoproxil [TDF]). The rate of undetectable HBV DNA increased in both treatment-experienced and naive patients. In TDF-experienced patients, the rate of alanine transaminase (ALT) normalization increased slightly (1.6%) within 12 months, but the change was not statistically significant (p=0.766). Younger age, low albumin, and high body mass index and cholesterol were identified as risk factors for abnormal ALT after 12 months, but no linear relationship was detected. In TDF-experienced patients, renal and bone function indicators showed significant improvement three months after the transition to TAF and remained stable for 12 months.Conclusion: Real-life data demonstrated effective virological and biochemical responses with TAF therapy. After switching to TAF treatment, gains in kidney and bone functions were achieved in the early period.en_US
dc.identifier.doi10.14744/hf.2022.2022.0043
dc.identifier.endpage68en_US
dc.identifier.issn1307-5888
dc.identifier.issn2757-7392
dc.identifier.issue2en_US
dc.identifier.pmid37250926en_US
dc.identifier.scopus2-s2.0-85164340106en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage61en_US
dc.identifier.trdizinid1178904en_US
dc.identifier.urihttps://doi.org/10.14744/hf.2022.2022.0043
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/1178904
dc.identifier.urihttps://hdl.handle.net/11616/92731
dc.identifier.volume4en_US
dc.identifier.wosWOS:001000795000004en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherKare Publen_US
dc.relation.ispartofHepatology Forumen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectHepatitis Ben_US
dc.subjectreal lifeen_US
dc.subjecttenofovir alafenamideen_US
dc.titleFirst year real life experience with tenofovir alafenamide fumarate: The pythagorean cohorten_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu